Trial
NCT00482053
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
—
Condition
Lymphoma, B-cell
Intervention
Autologous hematopoietic stem cell transplantation (auto-HSCT)
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-14